Biogen Idec Aims to Preserve MS Drug Avonex's Sales
Biogen Idec's (NASDAQ:BIIB) multiple sclerosis drug Avonex accounted for $2.2 billion or about 70% of the big biotech company’s product revenue through the first nine months of this year. So it stands to reason that the company wants to preserve those sales as best it can in the face of new competition. On Thursday Biogen said a study showed that an experimental drug -- essentially a long-acting version of its Avonex injectable treatment -- met goals for showing effectiveness in patients at both two-week and four-week dosings. Avonex is a once-weekly treatment. Biogen is testing the new drug known ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here